The timing of peanut exposure during infancy fundamentally reshapes immune system programming, offering parents a powerful tool to prevent one of childhood's most dangerous allergic conditions. This represents a complete reversal from previous medical guidance that recommended delaying peanut introduction until age three. Current evidence demonstrates that introducing peanut-containing foods between 4-6 months of age reduces peanut allergy development by approximately 70 percent in high-risk infants. The protective mechanism involves training developing immune cells to recognize peanut proteins as harmless rather than threats requiring inflammatory responses. For children who already have established peanut allergies, oral immunotherapy protocols show promise in desensitizing immune reactions. These treatments involve carefully graduated exposure to increasing amounts of peanut protein under strict medical supervision, allowing some patients to tolerate previously life-threatening exposures. However, immunotherapy carries significant risks including severe allergic reactions during treatment phases. The diagnostic landscape has also evolved beyond simple skin prick tests to include component-resolved diagnostics that identify specific peanut proteins triggering individual reactions. This precision allows clinicians to better predict reaction severity and treatment responses. The paradigm shift toward early introduction protocols represents one of allergy medicine's most significant advances, transforming peanut allergy from an increasingly common childhood burden into a largely preventable condition. Yet implementation requires careful medical guidance, particularly for infants with existing eczema or other food allergies who face elevated baseline risks.